Dampening immunity to promote bone metastasis
Nature Medicine
July 23, 2012
A novel pathway by which metastatic breast cancer cells dampen the body’s immune responses to thrive in bone is published online this week in Nature Medicine.
Belinda Parker and colleagues show that human bone metastasis have decreased amounts of Irf7, a master regulator of interferon responses that typically provide an enhanced immune response, and of its target genes. Deregulation of Irf7 by tumor cells accelerates bone metastasis by invoking the pro-tumorigenic help of myeloid-derived suppressor cells while keeping other anti-tumor immune effectors at bay.
The findings provide a new perspective on how metastatic tumors subvert innate immune responses and suggest the potential benefit of antimetastatic therapies targeting IFN signaling in people with breast cancer.
doi:10.1038/nm.2830
Research highlights
-
Dec 5
Astrophysics: Looking directly at the SunNature
-
Dec 4
Biomedical engineering: Neuron on a chipNature Communications
-
Dec 4
Environment: Levels of lithium in waterways of Seoul assessedNature Communications
-
Dec 3
Prenatal androgen exposure linked with polycystic ovarian syndrome riskNature Medicine
-
Dec 3
Climate Change: Hot temperatures and early childbirthNature Climate Change
-
Nov 29
Climate science: Amazon fires may enhance Andean glacier meltingScientific Reports
